![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PM Lippiello, M Bencherif, JA Gray, S Peters, G Grigoryan, H Hodges and AC Collins
Research & Development Department, R.J. Reynolds Tobacco Company, Winston-Salem, North Carolina, USA.
We have evaluated the physiological and behavioral effects of the CNS- selective nicotinic agonist (E)-N-methyl-4-(3-pyridinyl) -3-butene-1- amine (RJR-2403) using a number of different methods, including 1) reversal of pharmacologically induced amnesia in a step-through passive avoidance paradigm, 2) radial arm maze performance in rats with chemically induced brain lesions, 3) changes in HR and blood pressure in rats and 4) changes in body temperature, Y-maze activity, acoustic startle response and respiration in mice. Our results indicate that RJR- 2403 is equal to or better than nicotine on measures of CNS function and cognitive enhancement. Specifically, RJR-2403 significantly improved passive avoidance retention after scopolamine-induced amnesia and enhanced both working and reference memory in rats with ibotenic acid lesions of the forebrain cholinergic projection system in an 8-arm radial maze paradigm. By comparison, RJR-2403 was 15 to 30-fold less potent than nicotine in decreasing body temperature, respiration, Y- maze rears and crosses and acoustic startle response. RJR-2403 also demonstrated greatly reduced cardiovascular effects. RJR-2403 was approximately 10-fold less potent than nicotine in increasing HR and 20- fold less potent in increasing blood pressure. These results are consistent with in vitro data indicating this compound's high selectivity for CNS nicotinic ACh receptor subtypes relative to peripheral ganglionic and muscle-type nicotinic ACh receptors. Therefore, RJR-2403 may be a valuable tool for understanding the central and peripheral pharmacology of nicotinic cholinergic systems as well as a potential lead compound for the development of nicotinic therapeutics to treat neurological diseases where cholinergic neurotransmission has been compromised.
This article has been cited by other articles:
|
|
 |
|
  L. M. Broad, R. Zwart, K. H. Pearson, M. Lee, L. Wallace, G. I. McPhie, R. Emkey, S. P. Hollinshead, C. P. Dell, S. R. Baker, et al. Identification and Pharmacological Profile of a New Class of Selective Nicotinic Acetylcholine Receptor Potentiators J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1108 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. M. Shao and J. L. Feldman Pharmacology of Nicotinic Receptors in PreBotzinger Complex That Mediate Modulation of Respiratory Pattern J Neurophysiol, October 1, 2002; 88(4): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bontempi, K. T. Whelan, V. B. Risbrough, T. S. Rao, J. J. Buccafusco, G. K. Lloyd, and F. Menzaghi SIB-1553A, ({+/-})-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 297 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Damaj, W. Glassco, M. D. Aceto, and B. R. Martin Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 390 - 398. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Paylor, M. Nguyen, J. N. Crawley, J. Patrick, A. Beaudet, and A. Orr-Urtreger alpha 7 Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of Acra7-Deficient Mice Learn. Mem., September 1, 1998; 5(4): 302 - 316. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bencherif, J. D. Schmitt, B. S. Bhatti, P. Crooks, W. S. Caldwell, M. E. Lovette, K. Fowler, L. Reeves, and P. M. Lippiello The Heterocyclic Substituted Pyridine Derivative (±)-2-(-3-pyridinyl)-1-Azabicyclo[2.2.2]octane (RJR-2429): A Selective Ligand at Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 886 - 894. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
